(Q50568686)

15 March 2018

title

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

1 reference

9

1 reference

15 March 2018

Anne Laure Fauchais

11

1 reference

15 March 2018

author name string

Véronique Loustaud-Ratti

1

1 reference

15 March 2018

Sophie Alain

2

1 reference

15 March 2018

Annick Rousseau

3

1 reference

15 March 2018

Isabelle Fouchard Hubert

4

1 reference

15 March 2018

François Ludovic Sauvage

5

1 reference

15 March 2018

Pierre Marquet

6

1 reference

15 March 2018

François Denis

7

1 reference

15 March 2018

Françoise Lunel

8

1 reference

15 March 2018

Annie Lefebvre

10

1 reference

15 March 2018

Eric Liozon

12

1 reference

15 March 2018

Elisabeth Vidal

13

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 May 2008

1 reference

15 March 2018

published in

Hepatology

1 reference

15 March 2018

volume

47

1 reference

15 March 2018

issue

5

1 reference

15 March 2018

page(s)

1453-1461

1 reference

15 March 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

cites work

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.

21 January 2018

1 reference

Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

21 January 2018

1 reference

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

21 January 2018

1 reference

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

21 January 2018

1 reference

Pharmacokinetics of ribavirin in patients with hepatitis C virus

21 January 2018

1 reference

The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease

21 January 2018

1 reference

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

21 January 2018

1 reference

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

21 January 2018

1 reference

Antiviral action of ribavirin in chronic hepatitis C.

21 January 2018

1 reference

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.

21 January 2018

1 reference

Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection

21 January 2018

1 reference

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells

21 January 2018

1 reference

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

21 January 2018

1 reference

Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.22217

1 reference

15 March 2018

1 reference

15 March 2018